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Measurement of hepatic venous pressure gradient (HVPG) is a standard method for the
assessment of portal pressure and correlates with the occurrence of its complications. Liver
stiffness measurement (LSM) has been proposed as a noninvasive technique for the predic-
tion of the complications of cirrhosis. In this study, we evaluated the ability of LSM to
predict severe portal hypertension compared with that of HVPG in 61 consecutive patients
with HCV-related chronic liver disease. A strong relationship between LSM and HVPG
measurements was found in the overall population (r  0.81, P < 0.0001). However,
although the correlation was excellent for HVPG values less than 10 or 12mmHg (r 0.81,
P  0.0003 and r  0.91, P < 0.0001, respectively), linear regression analysis was not
optimal for HVPG values>10 mm Hg (r2 0.35, P< 0.0001) or>12 mm Hg (r2 0.17,
P  0.02). The AUROC for the prediction of HVPG >10 and >12 mm Hg were 0.99 and
0.92, respectively and at LSM cutoff values of 13.6 kPa and 17.6 kPa, sensitivity was 97%
and 94%, respectively. In patients with cirrhosis, LSM positively correlated with the pres-
ence of esophageal varices (P  0.002), although no correlation between LSM and esopha-
geal varices size was detected. The area under the ROC for the prediction of EV was 0.76 and
at a LSM cutoff value of 17.6 kPa sensitivity was 90%. Conclusion: LSM represents a
non-invasive tool for the identification of chronic liver disease patients with clinically sig-
nificant or severe portal hypertension and could be employed for screening patients to be
subjected to standard investigations including upper GI endoscopy and hemodynamic stud-
ies. (HEPATOLOGY 2007;45:1290-1297.)
See Editorial on Page 1087
Measurement of the hepatic venous pressure gra-dient (HVPG), currently employed for theevaluation of portal hypertension, has been
suggested as a reliable end-point to assess the therapeutic
benefit of antiviral therapy in patients with advanced he-
patic fibrosis due to chronic HCV infection.1 This sug-
gestion is based on two assumptions: (1) portal
hypertension is a direct consequence of the fibrotic trans-
formation of liver tissue, therefore HVPG provides a dy-
namic assessment of disease progression, and (2) HVPG
reflects the status of a significant portion of the liver and it
is not prone to sampling error as in the case of liver biopsy.
In addiction, considering the relative contraindications of
percutaneous liver biopsy in patients with advanced fibro-
sis or cirrhosis, measurement of HVPG could represent a
valuable method to evaluate disease progression in this
group of patients. Conversely, HVPG measurements is
invasive, relatively expensive, and available only in major
centers, indicating the need to develop reliable, non-inva-
sive, and widely available methods.
Transient elastography has been introduced as a rapid
and non-invasive technique that measures liver tissue
stiffness.2 Cohort studies have investigated its potential
use for the prediction of hepatic fibrosis stage in patients
with HCV-related chronic hepatitis.3,4 A recent study has
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proposed the use of transient elastography for the detec-
tion of cirrhosis and prediction of related complications
including the presence of esophageal varices and variceal
bleeding.5 In addition, another recent study has proposed
that liver stiffness measurement (LSM) is able to predict
the presence of large esophageal varices and could be use-
ful for selecting patients for endoscopic evaluation.6 The
possibility that transient elastography could serve as a
non-invasive alternative to HVPG is also suggested by the
study by Carrion and co-workers performed in patients
with HCV recurrence after liver transplantation.7 How-
ever, to what extent this assumption is valid for patients
with advanced fibrosis or cirrhosis who did not undergo
liver transplantation is unknown.
The aim of the current study was to evaluate the diag-
nostic accuracy of transient elastography compared with
that of HVPG measurement, used as a gold standard for
the assessment of portal hypertension, in a group of pa-
tients with HCV-related chronic liver disease with ad-
vanced fibrotic evolution.
Patients and Methods
Patients. Sixty-one consecutive patients (39 men and
22 women, mean age 55.6 11.7; age range 32-75 years)
with chronic HCV infection underwent HVPGmeasure-
ment between March 1, 2005 and July 1, 2006 upon
referral to the Hemodynamic Laboratory of our Institu-
tion. All patients had previous histopathological evidence
of cirrhosis (METAVIR F4)8 or a diagnosis of cirrhosis
suspected on the basis of standard clinical, ultrasono-
graphic, and biochemical parameters. These patients were
subjected to the hemodynamic study to obtain a basal
assessment of portal pressure before starting a prophylac-
tic treatment with beta-blockers (primary prophylaxis,
n 31) or to confirm the diagnosis of cirrhosis (n 30).
In this latter group of patients, a transjugular liver biopsy
was performed. All specimens were characterized by a
length 2.5 cm and included more that 11 portal tracts.
Histopathological analysis confirmed the diagnosis of cir-
rhosis in 16 patients (METAVIR F4) and revealed the
presence of advanced fibrosis in 14 patients (METAVIR
F3). Exclusion criteria were a body mass index 35, the
presence of ascites at clinical or ultrasound examinations,
the presence of other overt complications of cirrhosis in-
cluding cardiopulmonary and renal involvement, hepato-
cellular carcinoma, transaminases 10 upper limit of
normal, ongoing antiviral therapy, co-infection with
HBV and/or human immunodeficiency virus, active in-
fectious diseases other than HCV, any alcohol intake
within the 6 months preceding the study, previous deriv-
ative treatments for portal hypertension, concomitant
pre-sinusoidal and extrahepatic causes of portal hyperten-
sion, use of vasoactive drugs including beta-blockers, di-
uretics, and anti-inflammatory drugs, age younger than
18 or older than 75 years, and pregnancy. In each patient,
all experimental procedures were performed on the same
study day. In all patients but one, an upper GI endoscopy
was performed on the following day. Laboratory tests,
including serum bilirubin, albumin, ammonia, creati-
nine, blood urea nitrogen, aminotransferase (AST, ALT)
levels, platelet count, and international normalized ratio,
were performed in all patients within 1 week from the
study beginning. The study protocol was approved by the
Investigation and Ethics Committee of the Azienda Os-
pedaliero Universitaria Careggi, Firenze. The nature of
the study was explained to the patients, each of whom
provided written informed consent before the beginning
of the study, in accordance with the principles of the
Declaration of Helsinki (revision of Edinburgh, 2000).
Transient Elastography. After an overnight fasting,
patients underwent a complete upper abdomen ultra-
sound examination. Immediately after, transient elastog-
raphy was performed using the FibroScan apparatus
(Echosens, Paris, France), which consists of a 5-MHz ul-
trasound transducer probe mounted on the axis of a vi-
brator. Mild amplitude and low-frequency vibrations (50
Hz) are transmitted to the liver tissue, inducing an elastic
shear wave that propagates through the underlying liver
tissue. The velocity of the wave is directly related to tissue
stiffness. The tip of the transducer was covered with a
drop of gel and placed perpendicularly in the intercostal
space with the patient lying in dorsal decubitus position
with the right arm in the maximal abduction. Under con-
trol TM and A-mode, the operator choose a liver portion
within the right liver lobe at least 6 cm thick, free of large
vascular structures and gallbladder.3,4 Stiffness was mea-
sured on a cylinder of hepatic tissue of 1 cm of diameter
and 2 to 4 cm of length. The operator was a staff physician
(U.A.) who had previously performed at least 100 deter-
minations in patients with chronic liver disease. The me-
dian value of 10 successful acquisitions, expressed in
kilopascal (kPa), was kept as representative of the LSM.
As previously described in the literature4,7 and as sug-
gested by the provider of the instrumentation, we con-
sidered representative measurements 10 successful
acquisitions with a success rate of at least 60%, and with
an interquartile range lower than 20.
Measurements of HVPG and Transjugular Liver
Biopsy. Immediately after undergoing LSM, the patients
were transferred to the Hepatic Hemodynamic Labora-
tory. With the patient under local anesthesia, a venous
introducer was placed in the right internal jugular vein by
the Seldinger technique. A 7 French balloon-tipped cath-
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eter (Medi-Tech Boston Scientific Cork, Cork, Ireland)
was guided into the right hepatic vein for measurement of
wedged and free hepatic venous pressures. Adequacy of
occlusion was checked by injection of a small amount of
radiological contrast medium. The portal pressure gradi-
ent was measured as the HVPG, in other words, the dif-
ference between wedged and free hepatic venous
pressures.9 All measurements were performed at least in
triplicate, and permanent tracings were obtained on a
multi-channel recorder (PowerLab; ADI Instruments,
Milford, MA).10 Hemodynamic studies, evaluation, and
assessment of pressure tracing were performed by an ex-
perienced operator (F.V.) unaware of the results of tran-
sient elastography. Clinically significant portal
hypertension was defined as an HVPG 10 mm Hg ac-
cording a consensus definition.11 For transjugular liver
biopsy, a 16G needle (Cook, Bjaverskov, Denmark) con-
nected to a 20-mL syringe was introduced 2 to 4 cm
within the liver tissue while aspirating. This procedure
was repeated up to 5 times until an optimal tissue sample
was obtained. Tissue samples, processed and stained with
hematoxylin-eosin and Masson’s trichromic, were scored
by an expert pathologist unaware of the condition of the
patient and of the study protocol. Necroinflammatory
activity and fibrosis stage were scored according to the
METAVIR scoring system.8
Statistical Analysis. Statistical analysis was carried
out using the STATA Statistical Software Release 9.0 for
Windows (STATA Corp., College Station, TX). All re-
sults are expressed as mean  standard deviation (SD).
The unpaired Student t test was applied for comparisons
of normally distributed variables. The statistical signifi-
cance of inter-group differences, for non-normal distrib-
uted data, were evaluated by means of Kruskall-Wallis or
Wilcoxon rank-sum (Mann-Whitney) tests. Spearman
rank correlation coefficient was used when appropriate.
Linear regression analyses were calculated according to
the least squared methods. P values less than 0.05 were
considered statistically significant. The relationship be-
tween sensitivity and specificity of LSM at different cutoff
points, as predictor of patients with HVPG10 mm Hg
or patients with HVPG 12 mm Hg, and finally of pa-
tients with esophageal varices, was evaluated by receiver
operating characteristic (ROC) curves.12 Optimal liver
stiffness cutoff values were selected on the basis of sensi-
tivity, specificity, positive and negative predictive values
(NPV and PPV, respectively), positive and negative like-
lihood ratios (LR andLR, respectively).
Results
Characteristics of Patients. The major clinical and
biochemical parameters of the patients included in the
study are listed in Table 1. Among the 47 patients with







(n  14) F4 Versus F3
Age, y 55.6 11.7 57.8  10.9 48 11.4 P  0.002
Male gender, n (%) 39 (64%) 30 (63.8%) 9 (64.2%) P  NS
BMI, kg/m2 23 3 22  3.6 24 3.1 P  NS
Ex-drinker, n 5 5 0 -
Creatinine, mg/dl 0.94 0.28 0.96  0.31 0.86 0.11 P  NS
Bilirubin, mg/dl 1.34 0.83 1.47  0.89 0.92 0.37 P  0.01
Albumin, g/dl 3.58 0.76 3.33  0.67 4.43 0.33 P  0.0001
Platelet count, 109/l 127 64 107  48 193 66 P  0.0001
INR 1.22 0.47 1.32  1.08 1.20 0.18 P  NS
AST, U/l 61 23.51 65.64  20.87 52.17 15.39 P  0.04
ALT, U/l 72 17.87 71  20.56 75 15.75 P  NS
Child-Pugh A 28 (59.57%)
B 14 (29.79%)
C 5 (10.64%)








Variceal bleeding history 0
NOTE. Results are expressed as mean  SD.
Abbreviations: BMI, body mass index; MAP, mean arterial pressure; CRP, C-reactive protein; INR, international normalized ratio; AST, aspartate aminotransferases;
ALT, alanine aminotransferases; GOV, gastric esophageal varices; IGV, isolated gastric varices; PHG, portal hypertensive gastropathy; ND, not done; NS, not significant.
1292 VIZZUTTI ET AL. HEPATOLOGY, May 2007
previous or confirmed diagnosis of cirrhosis, 28 (59.57%)
were classified as Child-Pugh class A, 14 (29.79%) as
Child-Pugh class B, and 5 (10.64%) as Child-Pugh class
C. Considering the whole population, six patients
(9.83%) had no portal hypertension (i.e., HVPG5mm
Hg), 8 patients (13.11%) had a pre-clinical portal hyper-
tension (i.e., HVPG more than 5 but less than 10 mm
Hg), 47 patients (77.05%) had a clinically significant por-
tal hypertension (i.e., HVPG10 mm Hg), of whom 35
(57.38%) had severe portal hypertension (i.e., HVPG
12 mm Hg).13-17 Twelve patients were listed in the
HVPG range 10 12 mm Hg (19.67%). Esophageal
varices were present in 30 of 47 patients with cirrhosis,
gastroesophageal varices in 4, isolated gastric varices in 1,
and moderate to severe portal hypertensive gastropathy in
26. At the time of the study no patient with cirrhosis
showed clinical features of clinical decompensation (en-
cephalopathy, recent gastrointestinal bleeding, ascites, or
peripheral edema), or ultrasonographic evidence of HCC
and portal vein thrombosis. Patients with cirrhosis
showed significantly higher HVPG and liver stiffness
when compared with patients with advanced liver fibrosis
(P  0.0001 and P  0.0001, respectively). The success
rate of liver stiffness measurements was 90.22% 
14.72%, and the mean interquartile range 3.45 3.
Relationship Between HVPG and LSM. Consider-
ing the whole patient population, a statistically signifi-
cant, positive correlation between HVPG and LSM was
found (r  0.81, P  0.0001). Figure 1 illustrates linear
regression analysis between HVPG and LSM performed
in the complete study population (r2  0.61, P 
0.0001). In patients with HVPG 10 mm Hg or 12
mm Hg there was a statistically significant correlation
with LSM (r  0.81, P  0.0003 and r  0.91, P 
0.0001, respectively). Liver stiffness was significantly
higher in patients with an HVPG10 and12 mm Hg
than in patients with an HVPG 10 (P  0.0001) and
12 mm Hg (P  0.0001), respectively. Moreover, a
positive correlation also existed in patients with HVPG
10 mm Hg and, although less relevant, in patients with
HVPG12mmHg (r 0.59,P 0.0001 and r 0.37,
P  0.03, respectively). Figure 2 illustrates linear regres-
sion analysis in the different subgroups of HVPG. Note-
worthy, when patients with anHVPG value12mmHg
were considered, the correlation with LSMhardly reached
statistical significance, with very poor r values.
Non-invasive Prediction of Clinically Significant
Portal Hypertension (i.e., HVPG >10 mm Hg) and
Severe Portal Hypertension (i.e., HVPG >12 mm
Hg). Figure 3 shows the ROC curve of LSM for the
prediction of clinically significant portal hypertension
Fig. 1. Linear regression analysis between HVPG and LSM in whole
patient population. Abbreviations: HVPG, hepatic vein pressure gradient;
kPa, kilopascal.
Fig. 2. Linear regression analysis between
LSM (kPa) and different degrees of HVPG (mm
Hg). (A) Regression values for HVPG 10 mm
Hg and panel B for HVPG 10 mm Hg (r2 
0.72, P  0.0001 and r2  0.35, P 
0.0001, respectively). (C) Regression analysis
for HVPG 12 mm Hg and (D) for HVPG 12
mm Hg (r2  0.67, P  0.0001 and r2 
0.17, P 0.02, respectively). Between 10 and
12 mm Hg some scattering of values from the
theoretical regression line (C) was observed.
This became clearly evident for HVPG values
12 mm Hg (panel D). Abbreviations: HVPG,
hepatic vein pressure gradient; kPa, kilopascal.
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and severe portal hypertension. The areas under ROC
curves were 0.99  0.01 and 0.92  0.03, respectively.
Based on ROC curves, different cutoff values for LSM
were determined. A LSM13.6 kPa had a NPV of 92%
with a sensitivity of 97% for the prediction of patients
with HVPG 10 mm Hg. A LSM 17.6 kPa had an
NPV of 91% with a sensitivity of 94% for the prediction
of patients with HVPG 12 mm Hg. Table 2 summa-
rizes the best results for PPV, NPV, LR, and LR at
different LSM cutoff values.
Only 1 (7.69%) of 13 patients with LSM below 13.6
kPa, had clinically significant portal hypertension (i.e.,
HVPG10 mm Hg) and had no varices at endoscopy; 2
(9.09%) of 22 patients with LSM below 17.6 kPa had
Fig. 4. Relationship between HVPG (10 mm Hg, A; 12 mm Hg, B)
and LSM. HVPG is shown in the X-axis in mm Hg (number of patients in
parenthesis) and liver stiffness in Y-axis in kPa. Optimal LSM cutoff values are
indicated with a line. Abbreviations: HVPG, hepatic vein pressure gradient;
kPa, kilopascal; NPV, negative predictive value; PPV, positive predictive
value; LR, positive likelihood ratio; LR, negative likelihood ratio.
Table 2. Diagnostic Accuracy of Transient Elastography
S Sp PPV NPV LR -LR
HVPG 10 mmHg
13.6 kPa * 97% 92% 97% 92% 13.69 0.02
14.3 kPa 95% 93% 97% 76% 13.38 0.05
HVPG 12 mmHg
17.6 kPa * 94% 81% 86% 91% 4.88 0.08
16.3 kPa 97% 77% 84% 95% 4.20 0.04
EV
17.6 kPa * 90% 43% 77% 66% 1.58 0.23
27.4 kPa 70% 78% 90% 55% 3.27 0.28
NOTE. Diagnostic accuracy of transient elastography to predict HVPG  10
mmHg, HVPG 12 mmHg, and esophageal varices. Performance of different LSM
cutoff values for diagnosis of clinically significant, severe portal hypertension and
esophageal varices.
Abbreviations: S, sensitivity; Sp, specificity; PPV, positive predictive value; NPV,
negative predictive value; HVPG, hepatic vein pressure gradient; LR, positive
likelihood ratio; -LR, negative likelihood ratio; HVPG, hepatic venous pressure
gradient; EV, esophageal varices.
*Best LSM cutoff values chosen.
Fig. 3. Receiver operating characteristic curve showing the prediction
of clinical significant portal hypertension (i.e., HVPG10 mm Hg; A) and
severe portal hypertension (i.e., HVPG 12 mm Hg; B) with transient
elastography in the whole patient population. The ideal area under the
curve is 1.00. The straight line represents that based on chance alone
(area under the curve 0.50). The area under the ROC curves were 0.99
(0.01 standard error; 95% confidence index 0.92-0.99) and 0.92 (0.03
standard error; 95% confidence index 0.82-0.97), respectively.
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severe portal hypertension (HVPG 12 mm Hg), and
only 1 of them had small esophageal varices. Importantly,
none of the few false-negative cases had large esophageal
varices. Figure 4 illustrates the distribution of LSM values
according to the presence or absence of clinical signifi-
cant/severe portal hypertension.
Relationship Between LSM and Endoscopic Signs
of Portal Hypertension. Liver stiffness positively corre-
lated with the presence of esophageal varices by Wilcoxon
rank-sum test (P 0.002). No correlation between LSM
and the size of esophageal varices (small, F1, or large,
F2-F3) was found by Kruskall-Wallis test (chi-squared
NS). No esophageal varices, gastroesophageal varices, and
isolated gastric varices were observed in patients with a
LSM value below 14.4 kPa.
Non-invasive Prediction of Esophageal Varices.
Figure 5 shows the ROC curve of LSM for the prediction
of esophageal varices in patients with cirrhosis. The area
under the ROC curve was 0.76  0.07. Based on the
ROC curve, different cutoff values for LSM were deter-
mined. A LSM  17.6 kPa, identical to the cutoff pre-
dicting the presence of severe portal hypertension, had a
NPV of 66% with a sensitivity of 90% for the prediction
of varices in patients with cirrhosis. Table 2 summarizes
the best results for PPV, NPV, andLR,LR, at differ-
ent LSM cutoff values. Importantly, only 3 of 8 patients
(37.5%) with LSM below 17.6 kPa had esophageal vari-
ces, classified as small at upper GI endoscopy. The 95%
confidence interval for LR ranged from 0.98 to 2.52,
indicating the absence of a statistically significant capabil-
ity of identifying the presence of varices.
Complications Related to the Procedures. Two pa-
tients experienced a self-limiting supraventricular
arrhythmia during the hemodynamic study. No compli-
cations were associated with the execution of transient
elastography.
Discussion
The measure of disease progression represents a key
challenge in any of the different stages of chronic liver
disease. Indeed, a correct and reliable measure of the stage
of the disease has relevant implications for assessing the
effectiveness of the current therapeutic regimens and pre-
dicting the occurrence of complications. Accordingly, a
current major effort is directed at evaluating minimally
invasive procedures to be employed to substitute or inte-
grate the standard invasive methods, that is, liver biopsy
or the measurement of HVPG.
The cirrhotic transformation of the liver is associated
with structural and biological changes responsible for an
increase in portal pressure.18,19 These include major an-
gio-architectural modifications involving neo-angiogene-
sis and the presence of cell types undergoing active
contraction in response to an intra-hepatic predominance
of vasoconstrictor stimuli.20,21 As a result, the progressive
rise in portal pressure represents a reliable indicator of the
tissue changes and, to a certain extent, of the biological
microenvironment typical of fibrotic and cirrhotic liver.
These remarkable changes are also characterized by a pro-
gressive increase in liver tissue stiffness attributable to the
accumulation of fibrillar extracellular matrix. It is there-
fore conceivable that this latter parameter may also reflect
these changes, although with much less biological accu-
racy.
In agreement with this hypothesis, the results of the
current study show that a highly significant relationship
exists between LSM, measured by transient elastography,
and portal pressure in a population of patients chronically
infected by HCV at stages of fibrotic evolution ranging
from F3 to F4.
The threshold value of the HVPG for the formation of
varices is 10 mm Hg, whereas 12 mm Hg is the threshold
for the appearance of other complications, such as variceal
bleeding and ascites.13-17 In addition, as recently reported
in patients with compensated cirrhosis, an HVPG level
10 mm Hg represents a reliable predictor of clinical
decompensation in a median follow-up of 4 years.22 In-
terestingly, anHVPG value of 10 to 12mmHg appears to
be a key determinant in the relationship between HVPG
and LSM. Indeed, the correlation between the two pa-
rameters seems optimal for HVPG values 10 and 12
mm Hg, whereas it hardly reaches statistical significance
for values12 mm Hg. This important observation sug-
Fig. 5. Receiver operating characteristic curve showing the prediction
of esophageal varices with transient elastography in patients with cirrho-
sis. The ideal area under the curve is 1.00. The straight line represents
that based on chance alone (area under the curve, 0.50). The air under
the ROC curves was 0.76 (0.07 standard error; 95% confidence index
0.60-0.87).
HEPATOLOGY, Vol. 45, No. 5, 2007 VIZZUTTI ET AL. 1295
gests that beyond a certain degree of portal pressure, i.e.,
10 to 12 mm Hg, the development of portal hyperten-
sion becomes at least partially independent from the sim-
ple accumulation of fibrillar extracellular matrix
responsible for the increase in liver tissue stiffness. Indeed,
in advanced cirrhosis several extrahepatic factors such as
the hyperdynamic circulation, the splanchnic vasodilata-
tion, and the resistance opposed to portal blood flow by
the portosystemic collaterals contribute to the rise in por-
tal pressure.9,19 It is also likely that, beyond a certain de-
gree of cirrhotic transformation of liver tissue, the
measure of liver stiffness does not reflect the changes in
liver angio-architecture and the active contraction of scar
tissue secondary to the predominance of vasoconstrictors.
All together, these factors constitute important mechanis-
tic variables that can independently affect portal pressure
with a different impact in different patients.
With a cutoff of LSM 13.6 kPa, NPV and PPV for
the diagnosis of clinically significant portal hypertension
(i.e., HVPG 10 mm Hg) were 92% and 97%, respec-
tively. This observation is in agreement with previous
reports indicating cutoff values of 12.5 kPa and 14.5 kPa
for the diagnosis of liver cirrhosis.3,4,7 Moreover, the pres-
ence of severe portal hypertension (i.e., HVPG12 mm
Hg) could be suspected when a cutoff value17.6 kPa is
reached, with NPV and PPV of 91% and 86%, respec-
tively. This cutoff value for the presence of HVPG 12
mm Hg is in agreement with that preliminarily reported
by Lemoine and co-workers (17 kPa) in a mixed popula-
tion of HCV and alcoholic patients with cirrhosis.23
These results suggest that transient elastography could
represent a methodology for identifying patients with
HVPG values compatible with the development of portal
hypertension–related complications to be subjected to
further investigations including upper GI endoscopy and
hemodynamic studies. However, these results need to be
validated in larger populations, especially in those patients
with body mass index 30 kg/m2, in which LSM repro-
ducibility could not be optimal.
An additional important finding is the relation be-
tween LSM and the presence of esophageal varices. Al-
though LSM positively correlated with the presence of
esophageal varices, using a cutoff value of stiffness17.6
kPa, NPV and PPV for the detection of varices were 66%
and 77%, respectively, which are far from being satisfac-
tory. Moreover, this study failed to demonstrate a corre-
lation between LSM and variceal size, in disagreement
with the recent study performed by Kazemi and co-work-
ers in a larger series of patients with cirrhosis.9 However,
the cutoff value for the presence of large varices reported
by these authors (19 kPa) is characterized by low specific-
ity of the prediction that makes it difficult to be reliably
employed in clinical practice.24 Considering these obser-
vations and the importance of assessing the endoscopic
features of varices for predicting bleeding risk,25 it is not
advisable, at this time, to suggest transient elastography as
a surrogate of upper GI endoscopy.
A collateral observation of this study is the excellent
correlation between LSM and HVPG values 10 mm
Hg. Although this correlation needs to be further substan-
tiated in a large cohort of patients, it may have implica-
tions for the clinical assessment of patients at stages of
evolution of chronic liver disease preceding the develop-
ment of clinically significant portal hypertension. This is
in agreement with the study of Carrion and co-workers,
performed in patients with HCV recurrence after liver
transplantation.7 Indeed, no reliable non-invasive surro-
gate methods are available for the follow-up of patients
with advanced fibrosis before the occurrence of clinically
significant portal hypertension. In this context, transient
elastography could be useful in differentiating stages of
the progressive cirrhotic evolution of liver tissue once the
histological stage of cirrhosis has been reached. To address
this point, the results of the current study need to be
further confirmed in larger populations and in specifically
designed studies.
In summary, we suggest that measurement of liver
stiffness by transient elastography may represent a reliable
non-invasive methodology for the prediction of clinically
significant and severe portal hypertension, although not
good enough to replace endoscopy for the detection of
varices.
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